Here is what I'm reading this morning: Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks Pharma R&D Investments Moderating -- But Still High R&D Is Time Consuming and Expensive. Robotics, 3D Printing, & AR/VR Are Changing That. Fixing the Clinical Trial Bottleneck by Making Patients a Priority